先天性完整的心脏阻塞 - - 刺激 (什么时候?) 刺激还是不刺激?
Piotr Kukla1, Beata Podlejska1, Jerzy Wiliński2,3
1Department of Internal Medicine and Cardiology, Specialist Hospital H. Klimontowicza, 38-300 Gorlice, Poland.
Healthcare (Basel, Switzerland)
|June 26, 2024
概括
这个案例研究详细介绍了一位患有先天性完全心脏阻塞的年轻女性,她拒绝了心脏起器. 在她的心脏病评估中,萨尔布塔摩尔的使用证明是有益的.
科学领域:
- 心脏病学 心脏病学
- 电子生理学 电子生理学
- 遗传性心脏病是一种先天性心脏病.
背景情况:
- 异形先天性完全心脏阻塞是一种罕见的疾病.
- 患者可能多年保持无症状.
- 心脏起器植入是症状个体的标准治疗方法.
研究的目的:
- 介绍一个患有先天性完全心脏阻塞的年轻女性的病例,她拒绝植入心脏起器.
- 探索其他管理策略和诊断方法.
主要方法:
- 详细的患者病史和症状评估.
- 对心脏结构和功能的心声图评估.
- 运动测试和心电图 (ECG) 霍尔特监测.
- 对口服萨尔布塔摩尔的反应的评估.
主要成果:
- 这位患者在6岁时被诊断出患病,无症状.
- 进行了全面的心脏病评估.
- 口服萨尔布塔摩尔的使用显示出潜在的益处.
结论:
- 在无症状患者中,可以保守地管理先天性完全心脏阻塞.
- 对于治疗决策而言,彻底的心脏病学评估至关重要.
- 萨尔布塔摩尔在某些特定情况下可能提供治疗选择.
相关概念视频
Disturbances in Heart Rhythm
933
Arrhythmia or dysrhythmia refers to an abnormal heart rhythm caused by a defect in the heart's conduction system. It can cause the heart to beat irregularly, too quickly, or too slowly, leading to symptoms like chest pain, shortness of breath, and fainting. Factors such as stress, caffeine, alcohol, nicotine, cocaine, certain drugs, congenital defects, diseases, and electrolyte abnormalities can trigger arrhythmias.
Arrhythmias are categorized by their speed, rhythm, and origin. A slow...
Arrhythmias are categorized by their speed, rhythm, and origin. A slow...
933
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.3K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.3K
Conduction System of the Heart
5.6K
Autorhythmicity is a term that refers to the heart's inherent ability to generate electrical signals and instigate muscle contractions. This self-regulating conduction system within the heart consists of two key components: the pacemaker cells and specialized conducting cells.
The pacemaker cells are located in two primary nodes: the sinoatrial (SA) node and the atrioventricular (AV) node. The SA node pacemaker cells can autonomously depolarize, triggering an action potential that leads to the...
The pacemaker cells are located in two primary nodes: the sinoatrial (SA) node and the atrioventricular (AV) node. The SA node pacemaker cells can autonomously depolarize, triggering an action potential that leads to the...
5.6K
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
735
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
735
Electrophysiology of Normal Cardiac Rhythm
3.1K
The normal cardiac rhythm is a synchronized electrical activity that facilitates the regular and coordinated contraction of the heart muscle. This process is essential for efficient blood circulation throughout the body. The fundamental elements involved in establishing and maintaining this rhythm include the unique electrical properties of cardiac muscle cells, the sinoatrial (SA) node's pacemaker function, the specialized conducting system, and the ionic mechanisms underlying each phase...
3.1K
Depolarizing Blockers: Pharmocokinetics
317
Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
317


